AU2011340160B2

AU2011340160B2 - Composition for inhibiting the growth of mammalian hair

Info

Publication number: AU2011340160B2
Application number: AU2011340160A
Authority: AU
Inventors: Mrinmayee Kondhalkar
Original assignee: Individual
Current assignee: Individual
Priority date: 2010-12-08
Filing date: 2011-12-02
Publication date: 2017-10-12
Anticipated expiration: 2031-12-02
Also published as: GB2499769A8; AU2011340160A1; WO2012077024A1; GB2499769B; GB201311617D0; GB2499769A

Abstract

The invention relates to inhibiting hair growth. Particularly, the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damages the hair follicle, thereby disabling it to form a normal hair shaft.

Description

Compositionsfor inhibiting mammalian hair growth FIELD OF INVENTION:

The invention relatesto inhibiting hair growth.

Particularly, the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damagesthe hair follicle , thereby disabling it to form a normal hair shaft. INTRODUCTION:

Generally normal body hair growth is tolerated. But if there is excessive unwanted hair growth it affectsthe self-esteem of the person because of the social stigma.

Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic anti-androgens. These conventional procedures generally have drawbacks associated with them. PRIOR ART:

Asa rule normal body hair growth is tolerated. But if there isexcessive unwanted hair growth it affectsthe self-esteem of the person.

Various procedures have been employed to remove unwanted hair, including shaving, depilatory creams or lotion, waxing, plucking, electrolysis, therapeutic anti-androgens and laser. These conventional procedures generally have drawbacks associated with them.

The inventor herself has filed following patents on the subject, incorporated here as reference.

Indian patent application no IN/ 837/ 2004 dated 13th August 2004 (Granted Patent no: 237834) USpatent publication no US2006-0034952 A1 dated 16th February 2006 USpatent publication no US2008-0145330 A1 dated 19th June 2008 PCT patent application no PCT/ IN2005/000190 10th June 2005 SDuth Africa Granted patent no: 2007/2024 United Kingdom Granted Patent no: GB2434533 Australia Patent Application no: 2005270843 (Granted)

Indian Patent Application No337/MUIW2006 dated 09th March 2006 Indian Patent Application No998/MUIW2006 dated 16th March 2006 Indian Patent Application No 1296/ MUIW2006 dated 2131 August 2006

The inventor has discussed the use of the actives in different formsderived from the castor beansand related group of actives (cytotoxic lectins) for the inhibition of hair and hair f oli i cl e related actionsin these patent applications.

Castor bean is well known for its lipid constituent, castor oil and its medicinal properties especially as a purgative.

The ancient Science of Ayurveda describes many medicines made of castor oil and beans for variousapplicationssuch asfor general pain, inflammation, headache, abdominal pain, fever, asthma, cough, leucoderma, piles, Vaatnashak, used externally as a paste to treat inflammatory skin conditions, boils, carbuncles, abscesses, inflammation of the middle ear, and migraines.

Though the topical applications of castor are well known, they are not meant for the above-mentioned application.

Most of all, the above prior art other than patent applications filed by Inventor, does not mention use of the composition for specifically inhibit mammalian hair growth. Whereas, the claimed composition for specifically inhibiting mammalian hair growth is a novel invention and would offer an inexpensive method for inhibiting mammalian hair growth.

This invention seeksto overcome the limitationsof the prior art.

The object of this invention is to provide for a composition for inhibiting mammalian hair growth.

Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from castor beans.

Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from follicular delivery of aqueous extract of castor beans.

Another object of this invention isto provide for a composition using vesicular carriers which deliver the active i.e. Rcin in the extract directly to the hair follicle without causing allergic reaction.

Another object of this invention is to provide for a cytotoxic lectin (e.g. Rcin) composition using vesicular carriers for hair growth inhibition wherein purification of cytotoxic lectin (e.g. Rcin) i s not necessary.

Another object of this invention is to provide for a composition for inhibiting mammalian hair growth from follicular delivery of liposomized castor beansextract.

Another object of this invention isto provide for a composition that could be applied topically to the skin so asto damage the follicle, resulting in follicular destruction, thereby disabling it to form a hair shaft.

Another object of this invention is to provide the composition in the form of a paste, cream or gel which iseasy to apply, hasaesthetic appeal and hasgood spread ability.

Another object of this invention isto provide for a composition in the form of a paste, cream or gel that leavesno stainson application and isfree of preservatives.

Another object of this invention is to provide for a composition which could be packed conveniently i n jarsor tubes.

BACKGFOJND OF THE INVENTION

The invention relatesto inhibiting hair growth.

Particularly, the invention relates to composition for and method of inhibiting growth of mammalian hair with plant extract using liposomal delivery system which damagesthe hair follicle, thereby disabling it to form a normal hair shaft.

SUMMARY OF THE INVENTION

The present invention comprises of compositions for topical application for inhibiting unwanted mammalian hair growth by applying an effective amount of the composition to the skin of individuals in need to inhibit hair, including facial areas, legs, arms, armpits, and torso; irrespective of gender of the subject. The composition comprises of a hair-growth-inhibiting active agent dispersed in a dermatologically acceptable vehicle such as but not limiting to oil in water emulsion, gels, sustained release polymer films, sprays, soaps etc. 9milarly, vesicular carrierslike liposomes can be used for the selective follicular delivery of the hair-growth-inhibiting agent.

TECHNICAL FIELD

Rcin, which represents the type II ribosome inactivating proteins, isthe active ingredient in the castor bean that inactivatesthe hair follicle disabling it to form the hair shaft. Apart from ricin & its isomers, there is a group of allergens that are present in the castor bean. Rcin is water-soluble in nature, but also is present in castor oil in low concentrations. So, both aqueous extract and oil fraction can be used together or separately for the hair-growth inhibition. However, the allergic fraction causesboth immediate and delayed hypersensitivity reactions. So, it calls for the treatment of the extract to remove the allergens. Various extraction and purification procedures of the herbal extract arewell knowntothose skilled in the art. However, the present invention describes an innovative solution wherein castor bean extract, without purifying Rcin, can be used by encapsulating in a carrier like liposome, neosome or microspheres. Use of such vesicular carriers results in delivery of the active i.e. Rcin in the extract directly to the hair follicle without causing allergic reaction.

Before administration of the composition, herein described, in a preferred embodiment the hair is removed from the follicle e.g. by waxing or plucking or alternatively by other methods like shaving, depilation. Methods of hair removal which remove the hair from the follicle are known to initiate anagen, the growth phase of the hair cycle and also it exposes the hair follicle assembly responsible for the synthesis of hair shaft to the action of the composition herein described.

The topical compositions are the formulationscontaining therapeutically effective amountsof the respective active agent and pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such asbut not limitingto pH adjusting and buffering agents, toxicity adjusting agentsand the like, vesicular carriers like liposomes, microspheres, neosomes for carrying the active agent to the hair follicle, along with the usual components of the particular carrier like e.g. for oil in water emulsion, stearic acid and its derivatives, cetyl alcohol and its derivatives, mineral oils, citric acid, preservatives, fragrance, colours etc. or other such topical compositions as described in different pharmaceutical publications, resulting in aesthetically pleasing and easy to use formulations.

Examples:

Crude aqueousextractsof castor beansare used for liposome formulations.

Compositions:

Number of gel and oil in water emulsions were prepared using varying concentrations of the liposome suspension for animal aswell as human experiments.

Oil in water emulsion:

Mineral oil 26%

Cetyl alcohol 0.52%

Searicacid 0.94%

Cetostearyl alcohol 0.94%

Scdium alginate 0.36 %

Triethanolamine 0.1 %

Methyl Paraben 0.2%

Propyl paraben 0.01 %

Purified Water q.s.

Liposome suspension 10- 50 %

Gel:

Carbopol 940 1 %

Triethanolamine 1 %

Purified Water q.s.

Liposome suspension 10- 50 %

Liposome encapsulation Example1:

Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg and cholesterol 1.5 mg by ethanol injection method.

Example 2:

Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg and cholesterol 1.5 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.

Example 3:

Liposomes were prepared using Phospholipon 90 G (Lipoid) 15 mg by thin film formation method and hydrated with the extract (15 ml). Un-encapsulated extract is removed by centrifugation.

Example 4

Liposomes were prepared using Phospholipon 90 G (Lipoid) 10 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.

Example 5

Liposomes were prepared using &ya lecithin (Himedia) 10 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract is removed by centrifugation.

Example 6

Liposomes were prepared using Sbya lecithin (Himedia) 9 mg and DOPE 1 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract isremoved by centrifugation.

Example 7

Liposomes were prepared using Soya lecithin (Himedia) 8 mg and DOPE 2 mg by thin film formation method and hydrated with the extract (10 ml). Un-encapsulated extract isremoved by centrifugation.

Ali the formulations mentioned above showed reduction i n the number of hai r follicles, reduction in the darkness, length and thickness of the hair. Overall they changed the appearance of re-growing hair, both in animal experiments (mice) and humans. Also, the subjectsdid not show any adverse reaction to their skin.

At the end of the description of the invention, it should be understood that without departing from the spirit of the invention or the essential characteristics, it might be embodied in other variations. The embodiments described here should be considered as illustrative but not as restrictive.

Ali variations and forms, which come within the meaning and the range of equivalency of the claim, are intended to be embraced therein.

Claims

Listing of Claims:

1. A topical composition for inhibiting the growth of mammalian hair comprising a. Hair growth inhibiting active agent which is a liposome-encapsulated crude aqueous extract of Ricinus communis, wherein hair growth inhibiting active agent is prepared using phospholipids selected from lecithin, phosphatidylcholine (PC), phosphatidylethanolamine(PE), phosphatidylserine(PS), DOPE, ceramide and crude aqueous extract of Ricinus communis. b. Dermatologically acceptable vehicle c. Water (q.s.), wherein the hair growth inhibiting active agent is dispersed in a dermatologically acceptable vehicle so as to provide 10- 50% hair growth inhibiting active agent to the skin.

2. A topical composition for inhibiting mammalian hair growth as claimed in claim 1 wherein the composition is in the form of oil in water emulsion or gel.

3. A topical composition according to claim 1, wherein the liposomes are prepared using phospholipids

4. A topical composition according to claim 3, wherein the phospholipids used are selected from lecithin, phosphatidylcholine (PC), phosphatidylethanolamine(PE), phosphatidylserine(PS), DOPE, ceramide.

5. A topical composition according to claim 1, wherein the liposomes optionally contain cholesterol or cholesteryl esters.

6. A cosmetic method of inhibiting mammalian hair growth, comprising providing and applying a topical composition of any of the preceding claim to mammalian skin.

7. A cosmetic method of inhibiting mammalian hair growth as claimed in claim 6, wherein the topical composition is applied after removal of hair.

8. A cosmetic method of inhibiting human hair growth comprising a. Providing a safe method to manufacture a hair growth inhibiting active agent which is liposome-encapsuiated crude aqueous extract of Ricinus communis b. Dispersing the hair growth inhibiting active agent in a dermatologically acceptable vehicle c. Application of the cosmetic composition comprising 1050 % hair growth inhibiting active agent, which is liposome-encapsulated crude aqueous extract of Ricinus communis, to the skin.

9. Use of liposome encapsulated crude aqueous extract of Ricinus communis in the manufacture of a topical composition for inhibiting the mammalian hair growth; wherein the liposomes are manufactured using crude aqueous extract of Ricinus communis and phospholipids selected from lecithin, phosphatidylcholine (PC), phosphatidylethanolamine(PE), phosphatidylserine(PS), DOPE, ceramide and dispersed in the composition so as to provide 10 to 50 % liposome suspension.